The Quantellect read.As of Nov 19, 2026, 9 active firms cover Beam Therapeutics Inc: 7 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $26.00 to $80.00 (about 3.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $51.33 sits 144% above the current $21.02. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees revenue growth near -47% this year and 28% next, consensus EPS building from about $-1.24 next quarter toward $-5.01 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy778%
Neutral222%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$51.33
+144.2% upside
Average target across 9 active firms as of Nov 19, 2026 vs $21.02 current
Highest Target$80.00
Average Target$51.33
Lowest Target$26.00
Detailed analyst forecasts for BEAM
Showing 1–9 of 9 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 7 of 9 active firms rate BEAM a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BEAM EPS & revenue forecast
EPS · NEXT QUARTER
$-1.24
Range $-1.25 – $-1.23 · 2 analysts · +36% YoY
Next period, 2 analysts expect Beam Therapeutics Inc to earn $-1.24 a share (range $-1.25 – $-1.23), versus $-0.91 a year earlier. Full-year consensus is $-4.55, growing to $-5.01 the year after.
REVENUE · NEXT QUARTER
$378.5K
Range $300.0K – $500.0K · 2 analysts · +78% YoY
Revenue is expected to reach $378.5K (range $300.0K – $500.0K), +78.0% year-over-year. Full-year consensus is $38.5M, rising to $29.7M next year.
Top analysts covering Beam Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BEAM.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$65.00+209.2% to target
Overall win rate
48%
+ Follow
#2
Luca Issi
RBC Capital · Rank #76
Neutral
$26.00+23.7% to target
Overall win rate
49%
+ Follow
#3
Brian Cheng
JP Morgan · Rank #87
Buy
$44.00+109.3% to target
Overall win rate
51%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #223
Buy
$40.00+90.3% to target
Overall win rate
38%
+ Follow
#5
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$51.00+142.6% to target
Overall win rate
39%
+ Follow
BEAM stock forecast FAQ
What is BEAM's average 12-month price target?+
The 9 active firms with a live target average $51.33 for Beam Therapeutics Inc over the next 12 months, ranging from a $80.00 high to a $26.00 low, as of Nov 19, 2026.
Is BEAM stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BEAM?+
The Street-high target is $80.00 (HC Wainwright & Co.), and the Street-low is $26.00 (RBC Capital). The average of all 9 active-firm targets is $51.33.
How many active Wall Street firms cover BEAM?+
9 active firms have a recognized rating on Beam Therapeutics Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BEAM?+
Among analysts who currently cover BEAM, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $65.00 target.
What is Beam Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.24 per share (range $-1.25 – $-1.23) across 2 analysts. Full-year EPS is projected at $-4.55, rising to $-5.01 the following year.
How much revenue is Beam Therapeutics Inc expected to report next quarter?+
Consensus revenue is $378.5K (range $300.0K – $500.0K). Full-year revenue is projected at $38.5M, growing to $29.7M next year.
Have analysts been upgrading or downgrading BEAM lately?+
As of Nov 19, 2026, 7 of 9 active firms rate BEAM a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BEAM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.